Cart
sales@molnova.com
Atuveciclib Racemate
CAS No. 1414943-88-6
Atuveciclib Racemate ( BAY-1143572 Racemate )
Catalog No. M21757 CAS No. 1414943-88-6
Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 510 | In Stock |
|
| 10MG | 790 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAtuveciclib Racemate
-
NoteResearch use only, not for human use.
-
Brief DescriptionAtuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib.
-
DescriptionAtuveciclib (BAY-1143572) inhibits the proliferation of 7 MLL-rearrangements positive and negative AML cell lines with a median IC50 of 385 nM (range 230-1100 nM) and induces apoptosis. Atuveciclib (BAY-1143572) has potent and highly selective PTEFb-kinase inhibitory activity in the low nanomolar range against PTEFb/CDK9 and an at least 50-fold selectivity against other CDKs. Atuveciclib (BAY-1143572) shows a favorable selectivity against a panel of non-CDK kinases. It shows broad antiproliferative activity against a panel of tumor cell lines with sub-micromolar IC50 values. The concentration-dependent inhibition of the phosphorylation of the RNA polymerase II and downstream reduction of MYC mRNA and protein levels is observed.
-
SynonymsBAY-1143572 Racemate
-
PathwayAngiogenesis
-
TargetCDK
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1414943-88-6
-
Formula Weight387.43
-
Molecular FormulaC18H18FN5O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO : 100 mg/mL (258.11 mM; Need ultrasonic)
-
SMILESN=S(CC1=CC(NC2=NC(C3=CC=C(F)C=C3OC)=NC=N2)=CC=C1)(C)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Scholz A, et al. BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl)
molnova catalog
related products
-
FN-1501
FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).
-
LEE011
LEE011 is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.
-
LY-3177833
A potent and selective CDC7 inhibitor with IC50 of 3.3 nM.
